Even if interferons stay around in HCV therapy for many years to come, $1B in annual Lambda sales is a tall order, IMO.
Why? If IFN-L pans out (substantially better side effect profile and better efficacy - both strongly hinted at in ph i data) then it should pick of most of the IFN in HCV market fairly quickly. Witness the very rapid enrollment in the trials.
News 
Market Data 
Discover 
